Premium
Lacosamide monotherapy in clinical practice: A retrospective chart review
Author(s) -
Villanueva V.,
Giráldez B. G.,
Toledo M.,
De Haan G. J.,
Cumbo E.,
Gambardella A.,
De Backer M.,
Joeres L.,
Brunnert M.,
Dedeken P.,
Serratosa J.
Publication year - 2018
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/ane.12920
Subject(s) - lacosamide , tolerability , medicine , retention rate , retrospective cohort study , confidence interval , adverse effect , epilepsy , psychiatry , computer security , computer science
Objective To assess effectiveness and tolerability of first‐line and conversion to lacosamide monotherapy for focal seizures. Materials and Methods Retrospective, non‐interventional chart review of lacosamide monotherapy patients aged ≥16 years in Europe. Outcomes included retention rate at observational point ( OP ) 3 (12 ± 3 months), seizure freedom rates at OP 2 (6 ± 3 months) and OP 3 and adverse drug reactions ( ADR s). Results A total of 439 patients were included (98 first‐line and 341 conversion to monotherapy; 128 aged ≥65 years [25 first‐line and 103 conversion to monotherapy]). First‐line and conversion to monotherapy retention rates were 60.2% (59/98; 95% confidence interval [ CI ] 49.8%‐70.0%) and 62.5% (213/341; 57.1%‐67.6%), respectively. Kaplan‐Meier estimates of 12‐month retention rates were 81.2% and 91.4% for first‐line and conversion to monotherapy, respectively. First‐line and conversion to monotherapy retention rates in patients aged ≥65 years were 60.0% (38.7%‐78.9%) and 68.9% (59.1%‐77.7%), respectively. At OP 2, 66.3% of first‐line and 63.0% of conversion to monotherapy patients were seizure free. At OP 3, 60.2% of first‐line and 52.5% of conversion to monotherapy patients were seizure free. In the ≥65 years subgroup, seizure freedom rates at OP 2 were 72.0% and 68.0% for first‐line and converted to monotherapy, respectively, and at OP 3, 68.0% and 56.3%, respectively. Overall, 52 of 439 (11.8%) patients reported ADR s (16.4% in ≥65 years subgroup), most commonly dizziness (5.0%), headache (2.1%) and somnolence (1.6%). Conclusions Lacosamide was effective and well tolerated as first‐line or conversion to monotherapy in a clinical setting in adult and elderly patients with focal seizures.